Skip to main content

Table 3 Modifications in Metabolic Syndrome factors: control group and experimental group

From: Impact of high prebiotic and probiotic dietary education in the SARS-CoV-2 era: improved cardio-metabolic profile in schizophrenia spectrum disorders

 

Control Group (n = 21)

Intervention Group (n = 23)

 

Variables

Basal

6 months

p

Basal

6 months

p

P*

P**

Biochemical profile

 - Glucose (mg/dL)

94.5 (16.8)

102.6 (18.9)

0.03

93.7 (10.4)

97.5 (13.5)

0.023

0.814

0.259

 - HbA1c (%)

5.4 (0.4)

5.5 (0.3)

0.038

5.4 (0.3)

5.4 (0.6)

0.948

0.887

0.768

 - Cholesterol (mg/dL)

173.2 (45.4)

171 (43.9)

0.664

199.1 (38.4)

179.4 (64.3)

0.072

0.115

0.155

 - Triglycerides (mg/dL)

121.1 (67.4)

137.5 (75.8)

0.352

141.1 (74.3)

134.2 (69.4)

0.584

0.235

0.981

 - LDH (IU/L)

182.5 (22.5)

172.4 (29.9)

0.141

189 (30.6)

172.4 (29.9)

0.049

0.533

0.647

 - C-HDL (mg/dL)

50.2 (15.4)

48.4 (15.1)

0.067

49.7 (13.1)

52.4 (24.9)

0.611

0.962

0.760

 - C-LDL (mg/dL)

100.4 (33.8)

96.9 (33.7)

0.446

123 (32.4)

119.3 (41.6)

0.7

0.048

0.067

 - Total cholesterol/C-HDL (mg/dL)

3.6 (0.9)

3.6 (0.8)

0.522

4.2 (1.3)

4.2 (1.3)

0.905

0.058

0.180

Anthropometric Profile

 - Weight (kg)

76.6 (18)

75.8 (17.7)

0.382

85.7 (16.3)

81.3 (14.6)

 < 0.001

0.086

0.275

 - Waist circumference (cm)

100.9 (13.3)

101.2 (13.5)

0.818

105.7 (11.5)

102 (11.7)

 < 0.001

0.397

0.981

 - BMI (kg/m2)

27.5 (5.2)

27.2 (5.3)

0.323

29.5 (4.8)

27.9 (4.3)

 < 0.001

0.307

0.869

 - WHtR

0.59 (0.12)

0.61 (0.07)

0.345

0.61 (0.07)

0.59 (0.06)

 < 0.001

0.597

0.378

Cardiovascular Profile

 - SBP (mmHg)

125.5 (16.3)

129.8 (11.2)

0.124

128.7(13.9)

126.8 (10.6)

0.593

0.391

0.359

 - DBP (mmHg)

85.5 (9.7)

82.3 (7.9)

0.846

85.6 (11.5)

80.8 (7.5)

0.039

0.548

0.814

 - HR (bpm)

88.5 (16.4)

87.4 (14.2)

0.757

81.4 (12)

80.8 (9.4)

0.792

0.110

0.226

  1. p: intragroup statistical significance; p*: baseline intergroup statistical significance; p**: 6 months intergroup statistical significance; HbA1c Glycosylated haemoglobin, LDH Lactate dehydrogenase, C-HDL High-density lipoprotein, C-LDL Low-density lipoprotein, BMI Body mass index, WHtR Waist-to-height ratio, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR Heart rate, CG Evol. Control group evolution, IG Evol Intervention group evolution, % Balance  Percentage variation, REGICOR Calculation of 10-year coronary heart disease risk, SCORE Systematic coronary risk assessment for Spain, Antipsychotic DDD Defined daily dose antipsychotics